If ALK‐positive lung cancer can be predicted by tumor markers, such as CYFRA21‐1 positivity and the CYFRA21‐1:CEA ratio, we could prioritize the singleplex test for the ALK fusion gene at the initial stages of treatment. This evidence concerns the gene ALK and neoplasm.